Barry Ticho, Chief Medical Officer of Stoke Therapeutics, Inc. (NASDAQ:STOK), filed a Form 4 on September 3, 2026, reporting the sale of 5,545 shares of common stock on September 1, 2026, executed under a pre-established Rule 10b5-1 trading plan.
Key Highlights
- Shares sold in first transaction: 3,945 shares of common stock disposed of at a weighted average price of $30.512 per share on September 1, 2026.
- Shares sold in second transaction: 1,600 shares of common stock disposed of at a weighted average price of $31.0569 per share on September 1, 2026.
- Price ranges: The first sale occurred at prices ranging from $29.94 to $30.92 per share; the second at prices ranging from $30.96 to $31.20 per share.
- Beneficial ownership following transactions: 20,110 shares of common stock held directly after both sales.
- Trading plan: Both transactions were executed pursuant to a Rule 10b5-1 trading plan adopted by Ticho on November 19, 2025.
Stoke Therapeutics CMO Reports Two Common Stock Sales on September 1, 2026
According to the Form 4 filed with the SEC on September 3, 2026, Barry Ticho, serving as Chief Medical Officer of Stoke Therapeutics, Inc., disposed of a total of 5,545 shares of common stock on September 1, 2026, across two separate transactions. Both sales were carried out under a Rule 10b5-1 trading plan that the reporting person adopted on November 19, 2025, as disclosed in the filing's footnotes.
The first transaction involved 3,945 shares sold with a weighted average price of $30.512, with individual sale prices ranging from $29.94 to $30.92 per share, inclusive. Following that sale, Ticho's direct beneficial ownership stood at 21,710 shares. The second transaction involved 1,600 shares sold at a weighted average price of $31.0569, with prices ranging from $30.96 to $31.20 per share, inclusive. After this second sale, the filing reports his direct beneficial ownership at 20,110 shares.
The filing notes that because both reported prices are weighted averages, Ticho "undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth" in the footnotes. The Form 4 was signed by Jonathan Allan as Attorney-in-Fact on September 3, 2026. No derivative securities transactions were reported.
What Was Disclosed
The filing discloses two open-market sales of Stoke Therapeutics common stock by its Chief Medical Officer on September 1, 2026, totaling 5,545 shares, both executed under a previously adopted Rule 10b5-1 plan, leaving Ticho with 20,110 directly held shares.




Please wait processing your request...